NASDAQ:VRDN Viridian Therapeutics (VRDN) Stock Price, News & Analysis $24.26 +0.47 (+1.98%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Viridian Therapeutics Stock (NASDAQ:VRDN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Viridian Therapeutics alerts:Sign Up Key Stats Today's Range$23.46▼$24.4950-Day Range$13.47▼$24.2652-Week Range$10.93▼$24.75Volume821,047 shsAverage Volume1.13 million shsMarket Capitalization$1.55 billionP/E RatioN/ADividend YieldN/APrice Target$35.80Consensus RatingModerate Buy Company OverviewViridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.Read More… I want to be very real with you (Ad)Listen, I don’t come at my readers this direct very often, but here goes nothing: There is one strategy that has helped change my life and I’d like to think it has changed the lives of some of my readers, too. We’ve had success stories but I won’t even show you here because I don’t want you to get unrealistic expectations since individual results do vary. But the point is, this thing is the real deal. There’s a reason I consider it my flagship, even with all the market advantages I’ve discovered in recent years.Watch this URGENT training here! Viridian Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks54th Percentile Overall ScoreVRDN MarketRank™: Viridian Therapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 531st out of 1,013 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingViridian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageViridian Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Viridian Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Viridian Therapeutics are expected to decrease in the coming year, from ($3.94) to ($4.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Viridian Therapeutics is -5.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Viridian Therapeutics is -5.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioViridian Therapeutics has a P/B Ratio of 5.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Viridian Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.89% of the outstanding shares of Viridian Therapeutics have been sold short.Short Interest Ratio / Days to CoverViridian Therapeutics has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Viridian Therapeutics has recently decreased by 2.96%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldViridian Therapeutics does not currently pay a dividend.Dividend GrowthViridian Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted15.89% of the outstanding shares of Viridian Therapeutics have been sold short.Short Interest Ratio / Days to CoverViridian Therapeutics has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Viridian Therapeutics has recently decreased by 2.96%, indicating that investor sentiment is improving. News and Social Media1.5 / 5News Sentiment0.70 News SentimentViridian Therapeutics has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Viridian Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 5 people have searched for VRDN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Viridian Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Viridian Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $30,616,312.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 0.65% of the stock of Viridian Therapeutics is held by insiders.Read more about Viridian Therapeutics' insider trading history. Receive VRDN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viridian Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VRDN Stock News HeadlinesViridian Therapeutics, Inc. (NASDAQ:VRDN) COO Purchases $117,050.00 in StockOctober 1, 2024 | insidertrades.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Director Fairmount Funds Management Llc Purchases 1,600,000 SharesSeptember 18, 2024 | insidertrades.com$5k to $1.3m in just 3 tradesIt doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.October 17, 2024 | Insiders Exposed (Ad)Forecasting The Future: 13 Analyst Projections For Viridian TherapeuticsSeptember 26, 2024 | benzinga.comBuy Rating for Viridian Therapeutics: Leading the TED Market with Innovative SC Treatment VRDN-003September 26, 2024 | markets.businessinsider.comRBC Capital Sticks to Its Buy Rating for Viridian Therapeutics (VRDN)September 20, 2024 | markets.businessinsider.comCritical Insights From Viridian Therapeutics Analyst Ratings: What You Need To KnowSeptember 11, 2024 | benzinga.comBuy Rating Affirmed for Viridian Therapeutics on Successful THRIVE Trial and Market PotentialSeptember 11, 2024 | markets.businessinsider.comSee More Headlines VRDN Stock Analysis - Frequently Asked Questions How have VRDN shares performed this year? Viridian Therapeutics' stock was trading at $21.78 at the beginning of the year. Since then, VRDN stock has increased by 11.4% and is now trading at $24.26. View the best growth stocks for 2024 here. How were Viridian Therapeutics' earnings last quarter? Viridian Therapeutics, Inc. (NASDAQ:VRDN) issued its earnings results on Thursday, August, 8th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by $0.15. The firm had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.09 million. Viridian Therapeutics had a negative net margin of 79,185.77% and a negative trailing twelve-month return on equity of 83.18%. Who are Viridian Therapeutics' major shareholders? Viridian Therapeutics' top institutional shareholders include SG Americas Securities LLC (0.03%). Insiders that own company stock include Fairmount Funds Management Llc, Jonathan Violin, Scott Dunseth Myers, Lara Meisner, Stephen F Mahoney, Thomas W Beetham and Barrett Katz. View institutional ownership trends. How do I buy shares of Viridian Therapeutics? Shares of VRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Viridian Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Viridian Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET). Company Calendar Last Earnings8/08/2024Today10/17/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:VRDN CUSIPN/A CIK1590750 Webwww.viridiantherapeutics.com Phone(617) 272-4600Fax760-537-4101Employees50Year FoundedN/APrice Target and Rating Average Stock Price Target$35.80 High Stock Price Target$61.00 Low Stock Price Target$20.00 Potential Upside/Downside+47.6%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($4.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-237,730,000.00 Net Margins-79,185.77% Pretax Margin-79,185.77% Return on Equity-83.18% Return on Assets-44.82% Debt Debt-to-Equity Ratio0.05 Current Ratio15.82 Quick Ratio15.82 Sales & Book Value Annual Sales$310,000.00 Price / Sales4,999.91 Cash FlowN/A Price / Cash FlowN/A Book Value$4.48 per share Price / Book5.42Miscellaneous Outstanding Shares63,890,000Free Float63,475,000Market Cap$1.55 billion OptionableOptionable Beta1.08 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:VRDN) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMassive trading opportunity begins by October 21 October 21 could spark a mania among “next-generation” AI stocks. That’s the newest prediction from a Wall Str...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viridian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.